Author:
Yang Liuhong,Wu Penghui,Xu Jinchao,Xie Dihuan,Wang Zhongqing,Wang Qian,Chen Yong,Li Chuan Hua,Zhang Jiaxin,Chen Hangping,Quan Guilan
Publisher
Springer Science and Business Media LLC
Subject
Drug Discovery,Pharmaceutical Science,Agronomy and Crop Science,Ecology,Aquatic Science,General Medicine,Ecology, Evolution, Behavior and Systematics
Reference45 articles.
1. Schett G, Sloan SV, Stevens MR, Schafer P. Apremilast: a novel PDE4 inhibitor in the treatment of autoimmune and inflammatory diseases. Ther Adv Musculoskel. 2010;2(5):271–8.
2. FDA (2014). US Department of Health and Human Services, Food and Drug Administration Centre for Drug Evaluation and Research (CDER), Guidance for Industry, Clinical Pharmacology and Biopharmaceutics review, March 2014.
3. Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83(12):1583–90.
4. EMA. Assessment report on Otezla (apremilast). CHMP, EMA. 2014;2014.
5. Jinno J, Kamada N, Miyake M, et al. Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs. J Control Release. 2006;111(1-2):56–64.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献